Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Presentation Confirms Venclexta/Venclyxto Monotherapy Benefit in Certain Patients With High-Risk Chronic Lymphocytic Leukaemia and its Potential in Other Hard-to-Treat Blood Cancers

(Roche) June 23, 2017 - Roche today announced new data from multiple studies of Venclexta®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. Data presented in relapsed or refractory chronic lymphocytic leukaemia (CLL) confirmed the efficacy of Venclexta/Venclyxto with high and durable response rates and a well-tolerated safety profile in this high-risk population, including people with 17p chromosomal deletion who had previously received treatment.

Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar

(Pfizer) June 22, 2017 – Pfizer Inc. today announced that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for its proposed epoetin alfa biosimilar.

U.S. Physicians Move to More Flexible Mammogram Schedule

(Reuters Health) June 22, 2017 - Women at average risk for breast cancer should be offered screening mammograms every year or two starting at age 40 and they should start regular screening no later than age 50, an influential U.S. group of obstetricians and gynecologists said on Thursday.

Promises Made To Protect Preexisting Conditions Prove Hollow

(Kaiser Health News) Updated June 23, 2017 - Senate Republicans praised the Affordable Care Act replacement bill they presented Thursday as preserving coverage for people with cancer, mental illness and other chronic illness.

Novartis Announces Half of Eligible Ph+ CML-CP Patients Remain in Treatment-free Remission (TFR) Nearly Two Years After Stopping Tasigna® (nilotinib)

(Yahoo! Finance) June 23, 2017 - Novartis today announced new data from two clinical trials, ENESTfreedom and ENESTop, which demonstrate that approximately half of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic phase (CP), were able to maintain TFR after stopping treatment with Tasigna (nilotinib) both in the first-line setting and after switching from Glivec (imatinib)

Novartis Breast Cancer Drug Kisqali Wins European Panel Backing

(Reuters) June 23, 2017 - A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Editorial: The Senate’s Unaffordable Care Act

(New York Times) June 23, 2017 - The bill’s real aim is to cut taxes for the rich at the expense of health services that millions depend on.

NEJM Publishes Full Analysis of Rydapt® (midostaurin) Phase III RATIFY Trial In Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

(Novartis) June 23, 2017 - Novartis today announced that full results from the Rydapt [®] (midostaurin) Phase III RATIFY (CALGB 10603 [Alliance]) clinical trial were published in The New England Journal of Medicine (NEJM).

Cambridge’s Aveo Eyes Turnaround As Cancer Drug Nears E.U. Nod

(Boston Business Journal) June 23, 2017 - Aveo said Friday that European regulators are expected to reach a decision on tivozanib in about two months.

Bluebird Bio’s Gene Therapy For Blood Disorders Yields Some Impressive Results ― But Also Raises Questions

(STAT) June 23, 2017 - Bluebird is testing a gene therapy for two inherited blood disorders ― and the data managed both to impress and to leave important questions unanswered.